Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GREEN: Obinutuzumab Safety Study in CLL
NCT01905943Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2013
- Primary completion
- Dec 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 31
01
Overview
A Phase 3 trial of obinutuzumab in chronic lymphocytic leukemia (CLL), sponsored by Roche. Started Nov 2013; status: completed.
02
Drugs
obinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01905943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01905943.